Safe and Effective Delivery of Supplemental Iron to Healthy Older Adults: the Double-Blind, Randomized, Placebo-Controlled Trial Protocol of the Safe Iron Study
Erin D. Lewis,Edwin F. Ortega,Maria Carlota Dao,Kathryn Barger,Joel B. Mason,John M. Leong,Marcia S. Osburne,Loranne Magoun,Felix J. Nepveux,Athar H. Chishti,Christopher Schwake,Anh Quynh,Cheryl H. Gilhooly,Gayle Petty,Weimin Guo,Gregory Matuszek,Dora Pereira,Manju Reddy,Jifan Wang,Dayong Wu,Simin N. Meydani,Gerald F. Combs Jr
DOI: https://doi.org/10.3389/fnut.2023.1230061
IF: 5
2023-01-01
Frontiers in Nutrition
Abstract:The forms of iron currently available to correct iron deficiency have adverse effects, including infectious diarrhea, increased susceptibility to malaria, inflammation and detrimental changes to the gut microbiome. These adverse effects limit their use such that the growing burden of iron deficiency has not abated in recent decades. Here, we summarize the protocol of the “Safe Iron Study”, the first clinical study examining the safety and efficacy of novel forms of iron in healthy, iron-replete adults. The Safe Iron Study is a double-blind, randomized, placebo-controlled trial conducted in Boston, MA, USA. This study compares ferrous sulfate heptahydrate (FeSO4·H2O) with two novel forms of iron supplements (iron hydroxide adipate tartrate (IHAT) and organic fungal iron metabolite (Aspiron™ Natural Koji Iron)). In Phase I, we will compare each source of iron administrated at a low dose (60 mg Fe/day). We will also determine the effect of FeSO4 co-administrated with a multiple micronutrient powder and weekly administration of FeSO4. The forms of iron found to produce no adverse effects, or adverse effects no greater than FeSO4 in Phase I, Phase II will evaluate a higher, i.e., a therapeutic dose (120 mg Fe/day). The primary outcomes of this study include ex vivo malaria (Plasmodium falciparum) infectivity of host erythrocytes, ex vivo bacterial proliferation (of selected species) in presence of host plasma and intestinal inflammation assessed by fecal calprotectin. This study will test the hypotheses that the novel forms of iron, administered at equivalent doses to FeSO4, will produce similar increases in iron status in iron-replete subjects, yet lower increases in ex vivo malaria infectivity, ex vivo bacterial proliferation, gut inflammation. Ultimately, this study seeks to contribute to development of safe and effective forms of supplemental iron to address the global burden of iron deficiency and anemia. Registration: ClinicalTrials.gov identifier: NCT03212677; registered: 11 July 2017.